Administration of Schwann Cell‐Like Cells Differentiated From Tonsil‐Derived Mesenchymal Stem Cells Promotes Peripheral Nerve Regeneration by Inducing Macrophage Polarization in a Chronic Constriction Injury Model Authors: Yu Hwa Nam, Ji‐Sup Kim, Yoonji Yum, Juhee Yoon, Youbeen Cho, Jaeseung Lim, Saeyoung Park, Sung‐Chul Jung Published: 2026 ABSTRACT ABSTRACTIntroduction/AimsSchwann cell‐like cells (TMSC‐SCs) differentiated from human tonsil‐derived mesenchymal stem cells (TMSCs) secrete many factors related to nerve regeneration. This study aimed to explore the potential of TMSC‐SCs as a therapeutic agent for peripheral nerve regeneration using an animal model of chronic constriction injury (CCI) of peripheral nerves.MethodsIn this study, TMSCs or TMSC‐SCs mixed with fibrin glue were administered to the sciatic nerves of CCI rats and observed for 2–8 weeks (Experiment 1). In addition, the mixture with fibrin glue and low‐ or high‐dose TMSC‐SCs (TMSC‐SC‐L or TMSC‐SC‐H) was administered to the same site and observed for 2–4 weeks (Experiment 2). After administration, peripheral nerve and gastrocnemius muscle regeneration and recovery of motor function were confirmed through nerve conduction studies and histopathological observations. The expression of M1 and M2 macrophage markers was examined after TMSC‐SC treatment.ResultsBased on nerve conduction studies, myelination assessments, and gastrocnemius muscle observations, the TMSC‐SC‐H‐treated group showed a significant regeneration effect compared with the TMSC or TMSC‐SC‐L‐treated group. Additionally, compared to the TMSC‐SC‐L group (M1: 1.02 ± 0.15, M2: 0.73 ± 0.06), downregulation of M1 and upregulation of M2 macrophage markers were observed in the TMSC‐SC‐H group (M1: 0.47 ± 0.03, M2: 1.04 ± 0.11) by Western blotting.DiscussionThese results suggest that TMSC‐SCs could be developed as an allogeneic therapeutic agent to improve peripheral nerve regeneration in patients with peripheral nerve injury. These findings could serve as a test method to address unmet clinical needs for peripheral nerve regeneration. Abbreviations analysis of variance brain‐derived neurotrophic factor basic fibroblast growth factor chronic constriction injury compound muscle action potential Dulbecco's modified Eagle's medium fetal bovine serum fibrin glue hematoxylin and eosin hepatocyte growth factor immunohistochemistry myelin basic protein mesenchymal stem cell nerve conduction study nerve conduction velocity neurofilament heavy nerve growth factor platelet‐derived growth factor peripheral nerve injury partial sciatic nerve ligation Schwann cell standard error of the mean spared nerve injury spinal nerve ligation sciatic nerve transection transmission electron microscopy tonsil‐derived mesenchymal stem cell Schwann cell‐like cell differentiated from TMSC Western blotting Introduction Chronic constriction injury (CCI) is included in Class 2 of Seddon's three classifications of peripheral nerve injury (PNI), and is characterized by a destructive lesion of both the axon and its myelin sheath [1, 2]. This type of injury results in sensory and motor deficits, and nerve conduction and skeletal muscle abnormalities in the area of injury [3]. Methods for the nonsurgical treatment of CCI include electrical or magnetic stimulation, low‐intensity ultrasound, phototherapy, and photobiomodulation therapy [3, 4, 5, 6] as well as the use of nerve growth factors [7, 8, 9, 10, 11]. Cells, such as Schwann cells (SCs), mesenchymal stem cells (MSCs), skeletal muscle‐derived stem cells, neural crest stem cells, and skin‐derived precursor cells have also been administrated directly or indirectly into the nerves of CCI models with other carriers for the treatment [12, 13, 14, 15]. Stem cell‐derived secretome administration, gene therapy, pharmacological agents, and nutritional therapy are also being investigated [6, 16, 17]. After injury, peripheral nerves undergo axonal outgrowth driven by several factors, including immune cell infiltration, SC phenotype modification, and neurovascular regeneration [12]. During this period, SCs absorb phagocytic debris at the lesion site, recruit macrophages to create an optimal regenerative environment, and play a crucial role in nerve regeneration, including remyelination and axonal growth. Therefore, studies are underway to transplant SCs or SCs differentiated from stem cells for the treatment of PNI [14, 18, 19, 20, 21]. MSCs have been studied as important tools for tissue regeneration due to their ability to migrate to sites of injury and secrete bioactive factors, which are associated with paracrine effects and suppression of inflammatory responses that promote nerve regeneration [16]. Furthermore, MSCs play a crucial role in peripheral nerve regeneration due to their ability to produce and release neurotrophic factors that induce axonal growth, self‐renew, and differentiate into myelinating cells and Schwann‐like cells [12, 13, 16]. In particular, tonsil‐derived mesenchymal stem cells (TMSCs) exhibit high yield and proliferation rates among MSCs and have the potential to differentiate into Schwann cell‐like cells (TMSC‐SCs) [22]. Previous studies have confirmed the therapeutic efficacy of TMSC‐SCs in animal models of PNI created by partial sciatic nerve ligation (pSNL) or neurorrhaphy which was performed immediately after sciatic nerve transection (PNI‐neurorrhaphy) [23, 24]. For the construction of CCI models, it is common practice to leave the ligation in place to maintain continuous nerve compression and neuropathic pain. However, since long‐term compression can cause severe degeneration, fibrosis, and muscle atrophy, the removal of sutures is recommended in specific experiments, such as nerve repair and regeneration studies. This is also justifiable from an animal welfare perspective as it reduces irreversible damage. Based on these grounds, the sutures were removed in this study to minimize long‐term nerve damage and investigate nerve regeneration mechanisms [25, 26]. In this study, we created CCI rats as an animal model of sciatic nerve injury and evaluated the administration effects of TMSC‐SCs using various methods. This study aimed to explore the potential development of TMSC‐SCs as an allogeneic therapeutic agent to promote peripheral nerve regeneration in patients with peripheral nerve injury. Methods Culture of TMSCs and TMSC‐SCs Isolation and culture of TMSCs were performed as described in our previous study [22, 23]. The Institutional Review Board of Ewha Womans University Medical Center, Seoul, Republic of Korea, approved all experimental procedures used in this study (permit No. EUMC2019‐08‐004‐007). Written informed consent was obtained from the patients or their legal representatives prior to tonsil harvesting. The TMSC‐SCs were differentiated as described in a previous paper [23]. To culture the TMSC‐SCs, laminin‐coated cell culture dishes were used for culturing TMSC‐SCs (laminin was obtained from Sigma‐Aldrich, St. Louis, MO, USA). The culture medium consisted of Dulbecco's modified Eagle's medium/F12 (Welgene Inc., Daegu, Republic of Korea) supplemented with 10% fetal bovine serum (FBS, Invitrogen, Grand Island, NY, USA), 10 ng/mL basic fibroblast growth factor (bFGF, PeproTech, Cranbury, NJ, USA), 5 ng/mL platelet‐derived growth factor‐AA (PDGF, PeproTech), 14 μM forskolin (Sigma‐Aldrich, Saint Louis, MO, USA), and 5 ng/mL recombinant human heregulin‐β1 (Pepro Tech). Cells were stored in vials containing cryoprotectant (CryoStor CS10; CS10, BioLife Solutions, Bothell, WA, USA) and preserved in liquid nitrogen until therapeutic use. Administration The protocols used with the rats were approved by the institutional animal care and use committee of Ewha Womans University College of Medicine, and all experiments were performed in accordance with the approved guidelines and regulations (IACUC No. EWHA MEDIACUC 24‐008). Animals were housed in cages and maintained on a 12‐h light–dark cycle with free access to food and water. All efforts were made to minimize the suffering of animals. CCI model rats were produced using 7‐week‐old male Sprague–Dawley rats weighing 150–200 g, 1 week before administration of cells. Rats were placed on a heating pad with continuous isoflurane inhalation anesthesia for the duration of the surgery. To create the CCI model rats, four ligatures were tied around the sciatic nerve at 1 mm intervals for 1 week (Figure S1A), after which the sutures were removed (Figure S1B) [12]. The mixture of cells in 100 μL CS10 and/or 200 μL fibrin glue (FG, Baxter, Deerfield, IL, USA) [27] was transplanted with background material (Keisei Medical Industrial, Tokyo, Japan) (Figure S1C) [24], for which the detailed process is described in Figure S1D. Experimental Design The experimental scheme differs depending on the cells for which the transplantation effect is to be observed. To compare the therapeutic effects between undifferentiated TMSCs and differentiated TMSC‐SCs, NCS were performed at 2 and 4 weeks after administration, and histopathological evaluations of nerves and muscles were performed at 4 and 8 weeks (Experiment 1 (Exp. 1), Figure 1E). Experiment 2 (Exp. 2) was conducted to determine whether TMSC‐SCs, which showed a therapeutic effect in Exp. 1, showed differences in administration effect depending on the dose. Thus, we performed NCS and histopathological evaluations of nerves and muscles at 2 and 4 weeks after administration to evaluate the effects of low‐dose and high‐ TMSC‐SCs (TMSC‐SC‐L and TMSC‐SC‐H), and observed the expression of M1 and M2 macrophages in sciatic nerves harvested at 2 weeks (Figure 1F). The concentrations of TMSC‐SC‐L and TMSC‐SC‐H were determined based on the results of previous studies conducted in a PNI rat model. [24] Wild‐type (W) rats without CCI were used as positive controls, and the mice with only CCI or those administrated only FG were used as negative controls. The number of cells used and the experimental groups are described in Table 1. Confirmation of motor function in CCI rats after TMSCs and TMSC‐SCs administration by nerve conduction study. The graphs show the recovery profiles for each group at 2 and 4 weeks after treatment (A). Quantification of CMAP (B) and NCV (C) measurements in each group at 2 and 4 weeks after administration. In the graph, purple, blue, green, and orange bars represent the CCI (n = 4), FG (n = 4), FG + TMSC (n = 4), and FG + TMSC‐SC (n = 4) groups, respectively. Two‐way ANOVA was performed for comparison among groups and data are presented as mean ± SEM of three independent experiments (*p < 0.05; ***p < 0.001). CCI, chronic constriction injury group; CMAP, compound muscle action potential; FG + TMSC, fibrin glue+TMSC group; FG + TMSC‐SC, fibrin glue+TMSC‐SC group; FG, fibrin glue group; NCV, nerve conduction velocity; W, wild‐type group. TABLE 1Experimental groups of rats used in cell administration (Experiment 1 and 2).ExperimentClassification of groupsName of groupsCCIFibrin glueNumber of cellsVehicle (CS10)Number of animals1Negative controlCCIYes———6Negative controlFGYes200 μL—100 μL6TransplantFG + TMSCYes200 μL5 × 106 100 μL6TransplantFG + TMSC‐SCYes200 μL5 × 106 100 μL6Positive controlW————62Negative controlCCIYes———11Negative controlFGYes200 μL—100 μL11TransplantFG + TMSC‐SC‐LYes200 μL5 × 105 100 μL11TransplantFG + TMSC‐SC‐HYes200 μL5 × 106 100 μL11Positive controlW————11Abbreviations: CCI, chronic constriction injury; FG, fibrin glue; FG + TMSC, mixed treatment of fibrin glue and TMSCs (1 × 106); FG + TMSC‐SC, mixed treatment of fibrin glue and TMSC‐SCs (1 × 106); FG + TMSC‐SC‐H, mixed treatment of fibrin glue and high‐dose TMSC‐SCs (1 × 106); FG + TMSC‐SC‐L, mixed treatment of fibrin glue and low‐dose TMSC‐SCs (1 × 105); W, wild type. Experimental groups of rats used in cell administration (Experiment 1 and 2). Abbreviations: CCI, chronic constriction injury; FG, fibrin glue; FG + TMSC, mixed treatment of fibrin glue and TMSCs (1 × 106); FG + TMSC‐SC, mixed treatment of fibrin glue and TMSC‐SCs (1 × 106); FG + TMSC‐SC‐H, mixed treatment of fibrin glue and high‐dose TMSC‐SCs (1 × 106); FG + TMSC‐SC‐L, mixed treatment of fibrin glue and low‐dose TMSC‐SCs (1 × 105); W, wild type. Nerve Conduction Studies CCI rats were anesthetized with 3% isoflurane (Hana Pharm, Seoul, Korea) in an air mixture on a 37°C heating plate at 2 and 4 weeks after TMSC‐SC administration. For electrophysiological recordings and determination of compound muscle action potential (CMAP) and nerve conduction velocity (NCV), Nicolet Viking Quest apparatus (Natus Medical, San Carlos, CA, USA) was used. The fur on the distal back and hind limbs was completely removed, all positions of needle electrodes were marked before stimulating and recording, and disposable subdermal needle electrodes (TE/S43‐638, Technomed, Maastricht, Netherlands) were used. Stimulating electrodes were placed on the biceps femoris near the site of injury to obtain a distal response and on the gluteus maximus to obtain a proximal response, with a gap between the stimulating electrodes of 20 mm. The recording electrode site was placed in the gastrocnemius muscle, and the reference electrode site was placed in the Achilles tendon, while the ground electrode was on the tail. Immunohistochemistry Sciatic nerves at the site of injury administered with TMSCs or TMSC‐SCs were harvested at 4 and 8 weeks, and those administered with different doses of TMSC‐SCs were harvested at 2 and 4 weeks. The method used here for immunohistochemistry (IHC) was as described previously [24]. The manufacturers and catalog numbers of antibodies used for IHC are listed in Table S1. Hematoxylin and Eosin Staining The gastrocnemius muscles of rats transplanted with TMSCs and TMSC‐SCs were harvested at 4 and 8 weeks after administration, and the gastrocnemius muscles of rats transplanted with different doses of TMSC‐SCs were harvested at 2 and 4 weeks after administration. Tissues were stained with hematoxylin and eosin (H&E) for histological evaluation. Serial sections of 5 μm thickness were cut and stained with standard technique to determine the histological changes in the five groups. The stained slides were observed and photographed under a slide scanner (VS200, Olympus, Tokyo, Japan). Transmission Electron Microscopy At 2 and 4 weeks after administration with different doses of TMSC‐SCs, sciatic nerves were biopsied and fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Ultra‐thin sections were prepared for ultrastructural observations. The tissues were washed in 0.1 M phosphate buffer and post‐fixed with 1% osmium tetroxide in 0.1 M phosphate buffer (pH 7.4) for 1 h, dehydrated with ethanol, and embedded in epoxy resin. Ultra‐thin sections, approximately 70–80 nm in thickness, were cut with an ultramicrotome (EMUC7, DeerPark, IL, Leica) using a diamond knife. Sections were contrasted with 2% uranyl acetate followed by 0.25% lead citrate and observed with TEM (H‐7650, Hitachi, Tokyo, Japan) at an accelerating voltage of 80 kV. Western Blot Analyses WB analysis was performed as described previously [23]. The sciatic nerves of rats used for WB analysis were harvested at 2 weeks after administration in Experiment 2. The antibodies used for WB are listed in Table S2. Statistical Analysis All experiments were performed at least three times. Statistical analyses were performed using Prism, version 10 (GraphPad Software, San Diego, CA, USA). The results are presented as mean ± standard error of the mean (SEM). The observational results from IHC, TEM, and WB among the five groups were assessed for the significance of the differences by one‐way analysis of variance (ANOVA) and Tukey's post hoc multiple comparison test. In addition, the results of NCS were analyzed by two‐way ANOVA and Tukey's post hoc multiple comparison test. p < 0.05 was considered significant. Results Recovery of Nerve Conduction After Administration of TMSCs and TMSC‐SCs (Experiment 1) Representative graphs are shown for each experimental group (Figure 1A), through which CMAP and NCV responses were quantified. The peak in the graph was barely observed in the CCI and FG groups at 2 weeks but clearly observed at 4 weeks after administration. At 2 weeks, CMAP was the lowest in the CCI group compared with all other groups, but there was no significant difference between the groups. At 4 weeks after administration, CMAP was significantly increased in the FG + TMSC and FG‐TMSC‐SC groups compared with the CCI group, and in the FG + TMSC‐SC group compared with the CCI and FG groups (Figure 1B). At 2 and 4 weeks after administration, NCV increased in both the FG + TMSC and FG + TMSC‐SC groups compared with the CCI and FG groups, and in particular, the FG + TMSC‐SC group increased significantly more than the CCI group (Figure 1C). Recovery of Sciatic Nerve and Gastrocnemius Muscle After Administration of TMSCs and TMSC‐SCs (Experiment 1) The improvement of myelination was evaluated by the expression of myelin basic protein (MBP, green) and neurofilament heavy (NF‐H, red) through IHC staining of the sciatic nerve (Figure 2A,C). In the case of the W group, the cross‐section of myelin (MBP, green) surrounding the nerve (NF‐H) appears round like a doughnut. On the other hand, CCI rats displayed unmyelinated nerves or empty doughnut‐shaped myelin sheaths without nerves. The percentage of myelinated axons at 4 weeks after administration was significantly higher in the FG + TMSC group than in the CCI group, and significantly higher in the FG + TMSC‐SC group than in the other groups. In particular, the FG + TMSC‐SC group showed rapid myelination similar to the W group (Figure 2B). At 8 weeks after administration, the ratio of myelinated axons in the CCI group increased compared with the results at 4 weeks but was significantly lower than in the other experimental groups. The FG, FG + TMSC, and FG + TMSC‐SC groups all showed a similar level of increases (Figure 2D). Observation of neuromuscular regeneration in CCI rats after administration of TMSCs and TMSC‐SCs. Axon regeneration and myelin formation of sciatic nerves were confirmed by the expression of MBP (green) and NF‐H (red) at 4 (A) and 8 (C) weeks after treatment by IHC. Scale bars indicate 50 μm. The graphs show the percentage of myelinated axons, quantified to staining results at 4 (B) and 8 (D) weeks of administration using Image J software (Version 1.49, Apache Software Foundation), respectively. In the graph, purple, blue, green, and orange bars represent the CCI, FG, FG + TMSC, and FG + TMSC‐SC groups, respectively (n = 3). One‐way ANOVA was performed for comparison among groups and data are presented as mean ± SEM of three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Confirmation of gastrocnemius muscle regeneration after cell application using H&E staining. Histological changes of the muscle were determined at 4 (E) and 8 (F) weeks after treatment. The image of H&E staining was photographed under a light microscope. White arrows indicate rounded fibers. The scale bars indicate 50 μm. H&E, hematoxylin and eosin; IHC, immunohistochemistry; MBP, myelin basic protein; NF‐H, neurofilament heavy. Four weeks after administration, the CCI group, unlike the other groups, failed to achieve muscle fiber morphology through H&E staining. In addition, the FG, FG + TMSC, and FG + TMSC‐SC groups had smaller muscle fibers compared with those of the W group. Only the FG group exhibited round muscle fibers, rather than the normal hexagonal shape (Figure 3E). After 8 weeks of administration, the CCI group also exhibited round muscle fiber morphology and the size of the muscle fibers in all groups except the CCI group increased compared with those of the 4‐week period. Furthermore, round muscle fibers were observed only in the CCI and FG groups (Figure 2F). Confirmation of motor function by nerve conduction study in CCI rats after high‐ and low‐dose TMSC‐SCs administration. The graphs show the recovery profiles for each group at 2 and 4 weeks after treatment (A). Quantification of CMAP (B) and NCV (C) measurements in each group at 2 and 4 weeks after administration. In the graph, purple, blue, orange, and red bars represent the CCI (n = 4), FG (n = 4), FG + TMSC‐SC‐L (n = 4), and FG + TMSC‐SC‐H (n = 4) groups, respectively. Two‐way ANOVA was performed for comparison among groups and data are presented as mean ± SEM of three independent experiments (*p < 0.05; ***p < 0.001, ****p < 0.0001). CCI, chronic constriction injury group; CMAP, compound muscle action potential; FG + TMSC‐SC‐H, fibrin glue+TMSC‐SC‐high group; FG + TMSC‐SC‐L, fibrin glue+TMSC‐SC‐low group; FG, fibrin glue group; NCV, nerve conduction velocity; W, wild‐type group. Recovery of Nerve Conduction After Administration With Different Doses of TMSC‐SCs (Experiment 2) A representative graph is shown in Figure 3A. CMAP quantification at 2 weeks after administration did not differ among the experiment groups (Figure 3B). At 4 weeks after administration, CMAP increased in the FG + TMSC‐SC‐L group compared with the CCI and FG groups and significantly increased in the FG + TMSC‐SC‐H group compared with the CCI, FG, and FG + TMSC‐SC‐L groups (Figure 3B). The NCV results after administration showed that at 2 weeks, the FG + TMSC‐SC‐L and ‐H groups were not significantly different than the CCI and FG groups. At 4 weeks, the FG + TMSC‐SC‐H group significantly increased by about 2 times compared to the CCI, FG, and FG + TMSC‐SC‐L groups (Figure 3C). Recovery of Sciatic Nerve and Gastrocnemius Muscle After Administration of Different Doses of TMSC‐SCs (Experiment 2) In Exp. 2, the frequency of donut‐shaped myelinated nerves increased in the transplant group at 2 and 4 weeks after administration (Figure 4A,C). At 2 weeks after administration, the percentage of myelinated axons was significantly higher in the FG + TMSC‐SC‐H group compared with the CCI, FG, and FG + TMSC‐SC‐L groups (Figure 4B). At 4 weeks after administration, the percentage of myelinated axons in the FG, FG + TMSC‐SC‐L, and FG + TMSC‐SC‐H groups was significantly increased compared with the CCI group. In particular, the FG + TMSC‐SC‐H group was significantly increased compared with all experimental groups and increased to a level similar to that of the W group (Figure 4D). Observation of neuromuscular regeneration in CCI rats after administration with high‐ and low‐dose TMSC‐SCs. Axon regeneration and myelin formation of sciatic nerves were confirmed by IHC of MBP (green) and NF‐H (red) at 2 (A) and 4 (C) weeks after TMSC‐SCs application. Scale bars indicate 50 μm. The graphs show the percentage of myelinated axons, quantified to staining results using Image J software (Version 1.49, Apache Software Foundation) at 2 (B) and 4 (D) weeks of administration, respectively. In the graph, purple, blue, orange, red, and gray bars represent the CCI, FG, FG + TMSC‐SC‐L, FG + TMSC‐SC‐H, and W groups, respectively (n = 3). One‐way ANOVA was performed for comparison among groups and data are presented as mean ± SEM of three independent experiments (*p < 0.05; ***p < 0.001; ****p < 0.0001). Confirmation of gastrocnemius muscle regeneration after TMSC‐SCs application using H&E staining. Histological changes of the muscle were determined at 2 (E) and 4 (F) weeks after treatment. The image of H&E staining was photographed under a light microscope. White arrows indicate rounded fibers. The scale bars indicate 50 μm. H&E staining results at both 2 and 4 weeks showed that no muscle fiber shape was observed in the CCI group, and the round fibers were observed in the FG group (Figure 4E,F). After 2 weeks of administration, the muscle fiber size of all experimental groups was overall smaller than that of all experimental groups after 4 weeks (Figure 4E), and after 4 weeks of administration, the muscle fiber size was observed to be larger in the order of W, TMSC‐SC‐H, TMSC‐SC‐L, and FG groups (Figure 4F). Restoration of Sciatic Nerve Structure 2 and 4 Weeks After Administration With Different Doses of TMSC‐SCs (Experiment 2) To evaluate myelination of sciatic nerves administered TMSC‐SC after CCI, axons were observed in TEM images, the thickness of the myelin surrounding the axons was measured, and the G‐ratio was compared (Figure 5). At 2 weeks after TMSC‐SC administration, the diameter of the demyelinated nerve fibers and the thickness of the myelin sheath were significantly reduced in the CCI, FG, and FG + TMSC‐SC‐L groups compared with the W group, and increased in the FG + TMSC‐SC‐H group compared with the other experimental groups (Figure 5A–E). In addition, at 4 weeks, the morphology and thickness of the axons were improved in all experimental groups compared with those at 2 weeks, and in particular, the FG + TMSC‐SC‐H group showed the morphology of the myelinated nerve fibers was most similar to that of the W group (Figure 5G–L). After 2 weeks of administration, the G‐ratio of the FG group was slightly significantly reduced compared with the CCI group, and that of FG + TMSC‐SC‐H group was significantly reduced compared with all other groups (Figure 5F). After 4 weeks of administration, the G‐ratio of the FG + TMSC‐SC‐L and ‐H groups were significantly reduced compared with the CCI and FG groups and showed a tendency to decrease in a dose‐dependent manner (Figure 5L). Observation of myelination of the sciatic nerves in CCI rats using TEM after administration with high‐ and low‐dose TMSC‐SCs. Representative images at 5000× magnification of sciatic nerve cross‐sections in rats at 2 (A–E) and 4 (G–K) weeks after treatment are presented for each experimental group (CCI: (A) and (G); FG: (B) and (H); FG + TMSC‐SC‐L: (C) and (I); FG + TMSC‐SC‐H (D) and (J); W: (E) and (K)). The axon images were measured, followed by the quantification of the myelin thickness, indicating recovery of the sciatic nerve, based on the G‐ratio, at 2 (F) and 4 (L) weeks after treatment using Image J software (Version 1.49, Apache Software Foundation). In the graph, purple, blue, orange, red, and gray bars represent the CCI, FG, FG + TMSC‐SC‐L, FG + TMSC‐SC‐H, and W groups, respectively (n = 6). One‐way ANOVA was performed for comparison among groups and data are presented as mean ± SEM of three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). TEM, transmission electron microscopy. M1 and M2 Macrophages on Nerve Regeneration After Nerve Injury (Experiment 2) To investigate the effect of macrophages on nerve regeneration after nerve injury, rat sciatic nerves were harvested 2 weeks after administration of two doses of TMSC‐SCs. IHC was performed using CD86 antibodies (green) to identify M1, and CD206 antibodies (red) to identify M2 (Figure 6A–E). CD86 expression was upregulated in the injured nerves of CCI rats, indicating persistent inflammatory macrophage infiltration within the injured nerves. The CCI group expressed M1 markers predominantly (Figure 6A), whereas the W group expressed M2 markers predominantly (Figure 6E). In contrast, the FG group expressed both markers, either merged or separately (Figure 6B). In the TMSC‐SC‐L and ‐H groups, M2 markers were predominantly expressed, with M1 markers also weakly expressed (Figure 6C,D). However, the expression level and morphology of M2 markers in the TMSC‐SC‐H group were more similar to those in the W group. The whole sectional IHC images of each group were quantified (Appendix S1). The expression value of CD206 relative to CD86 was significantly higher in the TMSC‐SC‐H group than in the CCI, FG, and FG + TMSC‐SC‐L groups, showing a dose‐dependent trend (Figure 6F). Additionally, the expressions of CD86 and CD206 were compared between each group by WB (Figure 6G–I). CD86 expression was significantly decreased in the FG + TMSC‐SC‐H group compared with the CCI, FG, and FG + TMSC‐SC‐L groups (Figure 6H). CD206 expression was lowest in the CCI group and significantly increased in the FG + TMSC‐SC‐H group compared with the CCI, FG, and FG + TMSC‐SC‐L groups (Figure 6I). M1 and M2 macrophages' influence on nerve regeneration after high‐ and low‐dose TMSC‐SCs administration in CCI rat model. The expression of CD86 (green) and CD206 (red) as M1 marker and M2 marker in the sciatic nerve was compared at 2 weeks after treatment using IHC. Representative images observed at 630× magnification for each experimental group (CCI: (A); FG: (B); FG + TMSC‐SC‐L: (C); FG + TMSC‐SC‐H (D); W: (E)) and enlarged images of the purple boxed areas in each group are presented. Scale bars indicate 200 μm. The expression was quantified using Image J software, and the expression value of CD206 relative to CD86 was calculated and presented in a graph (F). One‐way ANOVA was performed for comparison among groups (n = 3) (***p < 0.001; ****p < 0.0001). (F) Expression of CD86 and CD206 in CCI rats by TMSC‐SCs administration using western blot, and the bands were quantitatively analyzed using Image J software. One‐way ANOVA was performed for comparison among groups (*p < 0.05; **p < 0.01; ****p < 0.0001). In the graph, purple, blue, orange, red, and gray bars represent the CCI, FG, FG + TMSC‐SC‐L, FG + TMSC‐SC‐H, and W groups, respectively (n = 3). Discussion In this study, we demonstrated that administration of TMSC‐SCs promotes peripheral nerve regeneration by inducing macrophage polarization in a CCI animal model. Application of TMSC‐SCs mixed with fibrin glue led to the efficient induction of peripheral nerve and related muscle regeneration and induced the transition of macrophages from pro‐inflammatory M1 to anti‐inflammatory M2. Cell therapy for PNI accelerates axonal regeneration and normalizes muscle function [28]. Human autologous SC transplantation after PNI has been reported to require approximately 30 days after injury to harvest, proliferate, and transplant stem cells from the damaged nerve stump during initial trauma surgery [29]. The TMSC‐SCs administered in this study were allogeneic cells stored frozen, thawed, and administered immediately with FG, so they are expected to be ready for use on the day of injury at clinical application. Concerns regarding stem cell therapy in clinical applications include safety, immunogenicity, functional heterogeneity, maintenance of biological activity, and the potential for malignancy. Clinical studies using autologous SC transplantation for PNI reported no adverse effects, such as malignancy, during long‐term follow‐up periods of more than 1 year [29, 30]. Furthermore, studies have reported that allogeneic TMSC‐SCs exhibited therapeutic effects without adverse effects in various animal models of peripheral nerve diseases [23, 24, 31]. Previous studies have shown that TMSC‐SCs expressed higher levels of neurotrophic factors, such as hepatocyte growth factor (HGF), neuregulin 1, nerve growth factor (NGF), and neurotrophic factor‐3, than TMSCs, and these factors exhibit a beneficial synergistic effect on the nerve regeneration process [32, 33]. This potential of TMSC‐SCs is believed to have led to improved motor function and nerve regeneration in rats following cell administration in this study. As in the CCI mice of this study, the therapeutic effect of these cells was confirmed in previous PNI–neurorrhaphy animal models [24, 31]. We performed two consecutive experiments with TMSCs and TMSC‐SCs in CCI rats in this study. Because of the IHC results of the sciatic nerve and the H&E staining results of the gastrocnemius muscle observed in Exp. 1, the CCI group, which only suffered injury, showed self‐recovery at 8 weeks after transplantation due to the characteristics of the rat model. Thus, the observation period in Exp. 2 of this study was advanced to 2 and 4 weeks after administration. NCS in CCI rats were generally performed 1 to 4 weeks post‐surgery to evaluate functional deficits of the sciatic nerve [34]. Since the critical period generally used to observe nerve damage progression and resulting neuropathic pain in CCI rats is considered to be within 30 days, we performed NCS only up to 4 weeks. In addition, since the phenotype of macrophages shows a gradual and steady transition from M1 to M2 within 3 to 5 days after injury, it is also considered an appropriate time to confirm the expression of CD86 and CD206 in the nerve tissue at 2 weeks after administration [35]. Macrophages stimulate immune responses that promote inflammation and repair damage by acting as important antigen‐presenting cells. In addition to these key roles, macrophages also activate the proliferation and division of SCs [36, 37]. After peripheral nerve injury, these cells then acquire stronger phagocytic and secretory capacities. These functions aid in the clearance of debris from the injury site and increase the release of key growth factors involved in nerve regeneration, including NGF and brain‐derived neurotrophic factor (BDNF), which are involved in the regeneration and proliferation of SCs [38, 39]. In this study, the expression patterns of CD86 and CD206 are associated with peripheral nerve regeneration, and the mechanism of this phenomenon may be related to HGF, which is involved in macrophage conversion [40]. In a previous study, TMSC‐SCs expressed higher levels of HGF than TMSCs, and exhibited therapeutic effects when administered to mice with PNI neurotrophic disorder. At that time, HGF expression was increased in the sciatic nerve, the site of administration, compared with mice administrated only the vehicle [24]. Therefore, the mechanism of the therapeutic effect of TMSC‐SC‐H in this study is proposed to be the transition of macrophages from M1 to M2. The CCI animal model has primarily been used for research on pain mechanisms. Nevertheless, we utilized this model based on the observation that it can be applied not only to pain but also to the evaluation of nerve regeneration and motor function recovery, as it is induced by CCI of peripheral nerves [12, 41]. Therefore, further study should evaluate pain‐related markers or behavioral experiments following TMSC‐SCs administration, too. In addition, while the CCI model has the advantage of being relatively simple to manufacture and highly reproducible, it also requires a level of skill as the degree of damage can vary depending on the tying strength [25]. Finally, further research is needed to identify specific secretory factors or molecules that influence the effects of FG + TMSC‐SC‐H administration and to confirm the in vivo distribution of the administered cells. In this study, a statistically significant therapeutic effect was observed in CCI rats administered FG + TMSC‐SC‐H. Notably, the conversion of expression to M2 from M1 macrophage markers in sciatic nerve tissue after 2 weeks of administration can be explained by the therapeutic mechanism of TMSC‐SCs for sciatic nerve injury recovery and nerve regeneration. These results suggest that TMSC‐SCs may have therapeutic potential in conditions other than PNI caused by crush, such as ligation and transection. To apply TMSC‐SCs to PNI treatment in the future, further studies are needed to verify the effects of nerve regeneration and neuromuscular junction recovery after administration in animal models such as CCI, pSNL, SNL, SNI, and SNT [42, 43]. Author Contributions Yoonji Yum: software, formal analysis, data curation. Yu Hwa Nam: software, formal analysis, data curation, writing – original draft, writing – review and editing, validation, visualization. Youbeen Cho: software, data curation, formal analysis. Ji‐Sup Kim: methodology, writing – original draft, writing – review and editing, data curation. Juhee Yoon: software, data curation, formal analysis. Saeyoung Park: conceptualization, methodology, data curation, writing – original draft, writing – review and editing, supervision, project administration, funding acquisition. Sung‐Chul Jung: conceptualization, methodology, data curation, writing – original draft, writing – review and editing, supervision, funding acquisition, project administration. Jaeseung Lim: resources, conceptualization. Funding This work was supported by Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (22C0627L1‐11 and 25A0204L1). Ethics Statement We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Conflicts of Interest Jaeseung Lim is the CEO/founder of Cellatoz Therapeutics Inc., Republic of Korea. The remaining authors have no conflicts of interest. Supporting information Figure S1: Scheme of the cell administration and schedule of the animal experiments. The administration scheme involved suturing and compressing the sciatic nerve of rats (A), releasing it one week later to induce nerve damage, and creating a CCI rat model (B). To ensure stable administration, a medical disposable background material is placed beneath the nerve (C), the mixture of fibrin glue and cells is implanted, wrapped with background material, allowed to harden for 1 min, and then background material is removed, as schematically represented in (D). Schedule of Experiment 1 after administration with FG + TMSC or TMSC‐SC (E). Schedule of Experiment 2 after administration with FG + TMSC‐SC‐L or TMSC‐SC‐H (F). CCI, chronic constriction injury; TMSC, tonsil‐derived mesenchymal stem cells, TMSC‐SCs, neuronal regeneration‐promoting cells; FG + TMSC, mixed treatment of fibrin glue and TMSCs (1 × 105); FG + TMSC‐SC, mixed treatment of fibrin glue and TMSC‐SCs (1 × 105); FG + TMSC‐SC‐L, mixed treatment of fibrin glue and low‐dose TMSC‐SCs (1 × 105); FG + TMSC‐SC‐H, mixed treatment of fibrin glue and high‐dose TMSC‐SCs (1 × 106); NCS, nerve conduction study; IHC, immunohistochemistry; H&E, hematoxylin and eosin stain; TEM, transmission electron microscopy; WB, Western blotting. Table S1: Information on the antibodies used for immunohistochemistry. Table S2: Information on the antibodies used for Western blotting. Appendix S1: Supporting Information.